Lantern Pharma (LTRN) Assets Average (2020 - 2026)
Lantern Pharma's (LTRN) quarterly Assets Average came in at $9.1 million in Q1 2026, down 60.88% YoY from $23.3 million in Q1 2025, and down 25.97% on a QoQ basis from $12.3 million in Q4 2025.
Lantern Pharma (LTRN) Assets Average (2020 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 7 years of Assets Average data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Assets Average fell 60.88% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 60.88% YoY) and the FY2025 annual result came in at $18.3 million, down 47.11% from the prior year.
- Assets Average retreated to $9.1 million in Q1 2026, from $12.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $71.2 million in Q1 2022 to a low of $9.1 million in Q1 2026.
- A 5-year average of $40.5 million and a median of $41.7 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average jumped 38.39% — and 2026, when it sank 60.88%.
- Tracing LTRN's Assets Average over 5 years: stood at $60.5 million in 2022, then dropped by 24.45% to $45.7 million in 2023, then sank by 38.89% to $27.9 million in 2024, then plunged by 55.85% to $12.3 million in 2025, then retreated by 25.97% to $9.1 million in 2026.
- The last three Assets Average figures came in at $9.1 million (Q1 2026), $12.3 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 19.82 Bn |
| 10 | Lantern Pharma | 25.99 Mn | 25.99 Mn | - | 9.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.13 Mn |
| Dec 31, 2025 | 12.33 Mn |
| Sep 30, 2025 | 15.52 Mn |
| Jun 30, 2025 | 19.26 Mn |
| Mar 31, 2025 | 23.33 Mn |
| Dec 31, 2024 | 27.93 Mn |
| Sep 30, 2024 | 32.94 Mn |
| Jun 30, 2024 | 37.66 Mn |
| Mar 31, 2024 | 41.69 Mn |
| Dec 31, 2023 | 45.71 Mn |
| Sep 30, 2023 | 49.60 Mn |
| Jun 30, 2023 | 53.47 Mn |
| Mar 31, 2023 | 57.17 Mn |
| Dec 31, 2022 | 60.50 Mn |
| Sep 30, 2022 | 64.27 Mn |
| Jun 30, 2022 | 67.39 Mn |
| Mar 31, 2022 | 71.18 Mn |
| Dec 31, 2021 | 75.78 Mn |
| Sep 30, 2021 | 80.02 Mn |
| Jun 30, 2021 | 82.47 Mn |